SCHEMBL15845841

SCHEMBL15845841

C[Si](C)(C)CCOCOc1cc(-c2ccc(C(=O)O)cc2)cc2c(=O)n(COCC[Si](C)(C)C)cnc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.38
▸ EGFR P00533 2/20 0.36
▸ RARB P10826 5/20 0.35
▸ RARA P10276 1/20 0.35
▸ RARG P13631 1/20 0.35
▸ MMP13 P45452 3/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ EIF4EBP1 Q13541 2/20 0.34
▸ IGF1R P08069 1/20 0.34
▸ SRC P12931 1/20 0.34
▸ FLT4 P35916 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ FLT3 P36888 1/20 0.34
▸ EPHB4 P54760 1/20 0.34
▸ TEK Q02763 1/20 0.34
▸ PTPN11 Q06124 1/20 0.33
▸ MAP4K4 O95819 1/20 0.33
▸ SLC22A8 Q8TCC7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15846413 0.91 EIF4EBP1 (0.42) EIF4EBP1
SCHEMBL15859688 0.90 EGFR (0.39) NPC1EGFRKDM4EKMT2AIGF1R
SCHEMBL15845858 0.87 EGFR (0.35) NPC1EGFRKDM4EIGF1RSRC
SCHEMBL15845596 0.86 EGFR (0.35) NPC1EGFRRARBRARARARG
SCHEMBL17391755 0.85 PTPN11 (0.37) NPC1EGFRIGF1RSRCFLT4
SCHEMBL15845688 0.85 EGFR (0.34) NPC1EGFRIGF1RSRCFLT4
SCHEMBL15846052 0.83 GRK2 (0.37) EGFRIGF1RSRCFLT4KDR
SCHEMBL15845861 0.83 HTT (0.36) NPC1EGFRMEN1KMT2AEIF4EBP1
SCHEMBL15845679 0.82 PTPN1 (0.32) EGFRKDM4EIGF1RSRCFLT4
SCHEMBL15845818 0.82 P2RX3 (0.38) NPC1EGFRKDM4EKMT2AIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9656971-B2 COMT inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-05-23 — — US disclosed
EP-2938600-B1 COMT INHIBITORS HOFFMANN LA ROCHE (CH) 2017-01-25 — — EP disclosed
US-20160002177-A1 COMT INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-01-07 — — US disclosed
EP-2938600-A1 COMT INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-11-04 — — EP disclosed
WO-2014102233-A1 COMT INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160002177-A1 COMT INHIBITORS COMT, PNMT, SLC6A3 NPC1 2621/4885EGFR 4189/4885RARB 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback